Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2012 - 2020)

Karyopharm Therapeutics has reported Current Deferred Revenue for 9 years, with the latest figure at $297000.0 in Q4 2020.

• For the quarter ending Q4 2020, Current Deferred Revenue fell 87.31% year-over-year to $297000.0; the trailing twelve-month figure through Dec 2020 stood at $297000.0 (down 87.31% YoY), and the FY2020 full-year result was $297000.0, down 87.31% from the prior year.
• Current Deferred Revenue for Q4 2020 stood at $297000.0, roughly flat from $297000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $21.9 million in Q4 2017, with the low at $178000.0 in Q1 2018.
• Historically, Current Deferred Revenue has averaged $2.6 million across 5 years, with a median of $297000.0 in 2020.
• Annual changes were most pronounced in 2017 — Current Deferred Revenue jumped 7728.93% — and 2018, when it plunged 98.22%.
• Karyopharm Therapeutics' Current Deferred Revenue stood at $280000.0 in 2016, then jumped by 7728.93% to $21.9 million in 2017, then sank by 98.22% to $390000.0 in 2018, then surged by 500.26% to $2.3 million in 2019, then tumbled by 87.31% to $297000.0 in 2020.
• The last three Current Deferred Revenue figures came in at $297000.0 (Q4 2020), $297000.0 (Q3 2020), and $297000.0 (Q2 2020), per Business Quant data.